CANCER:

Leiomyosarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	PTC596 Sensitive: B - Late Trials PTC596 Sensitive : B	PTC596 Sensitive: B - Late Trials PTC596 Sensitive : B
Chr amplification(4)(q22.1)	Leiomyosarcoma	Chr amplification(4)(q22.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(3)(q14.2)	Leiomyosarcoma	Chr del(3)(q14.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(11)(q25)	Leiomyosarcoma	Chr del(11)(q25)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(q14.1)	Leiomyosarcoma	Chr del(2)(q14.1)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr del(2)(p12)	Leiomyosarcoma	Chr del(2)(p12)	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
Chr del(1)(q44)	Leiomyosarcoma	Chr del(1)(q44)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q13.2)	Leiomyosarcoma	Chr amplification(8)(q13.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(8)(q22.2)	Leiomyosarcoma	Chr amplification(8)(q22.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(13)(q13.3)	Leiomyosarcoma	Chr amplification(13)(q13.3)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(20)(p12.2)	Leiomyosarcoma	Chr amplification(20)(p12.2)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
Chr amplification(4)(q26)	Leiomyosarcoma	Chr amplification(4)(q26)	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
ATRX mutation	Leiomyosarcoma	ATRX mutation	Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3	eribulin mesylate Resistant: C3 – Early Trials eribulin mesylate Resistant : C3
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3	eribulin mesylate Sensitive: C3 – Early Trials eribulin mesylate Sensitive : C3
ATRX mutation	Leiomyosarcoma	ATRX mutation	Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3	dacarbazine Resistant: C3 – Early Trials dacarbazine Resistant : C3
AKT1 mutation + mTOR mutation	Leiomyosarcoma	AKT1 mutation + mTOR mutation	Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
TMB-H	Leiomyosarcoma	TMB-H	Leiomyosarcoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MYH9-ALK + ALK-WDR43	Leiomyosarcoma	MYH9-ALK + ALK-WDR43	Leiomyosarcoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
PTEN mutation + TSC1 mutation	Leiomyosarcoma	PTEN mutation + TSC1 mutation	Leiomyosarcoma	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
NF1 mutation	Leiomyosarcoma	NF1 mutation	Leiomyosarcoma	IPN60090 Sensitive: C4 – Case Studies IPN60090 Sensitive : C4	IPN60090 Sensitive: C4 – Case Studies IPN60090 Sensitive : C4
YWHAE-JAZF1 fusion	Leiomyosarcoma	YWHAE-JAZF1 fusion	Leiomyosarcoma	regorafenib Sensitive: C4 – Case Studies regorafenib Sensitive : C4	regorafenib Sensitive: C4 – Case Studies regorafenib Sensitive : C4
PLK4 expression	Leiomyosarcoma	PLK4 expression	Leiomyosarcoma	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D
CSPG4 overexpression	Leiomyosarcoma	CSPG4 overexpression	Leiomyosarcoma	CSPG4.TNK Sensitive: D – Preclinical CSPG4.TNK Sensitive : D	CSPG4.TNK Sensitive: D – Preclinical CSPG4.TNK Sensitive : D
HAT1 overexpression	Leiomyosarcoma	HAT1 overexpression	Leiomyosarcoma	pazopanib Resistant: D – Preclinical pazopanib Resistant : D	pazopanib Resistant: D – Preclinical pazopanib Resistant : D
MAN1A1-ROS1 rearrangement	Leiomyosarcoma	MAN1A1-ROS1 rearrangement	Leiomyosarcoma	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D
TP53 mutation	Leiomyosarcoma	TP53 mutation	Leiomyosarcoma	selinexor + eribulin mesylate Sensitive: D – Preclinical selinexor + eribulin mesylate Sensitive : D	selinexor + eribulin mesylate Sensitive: D – Preclinical selinexor + eribulin mesylate Sensitive : D

Leiomyosarcoma

Associations(30)

Associations
(30)